

Table 4.26

Cancer of the Female Breast (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2004-2008
Females by Race

Histology ^a	All Races		White		Black		Asian/Pacific Islander		American Indian/ Alaska Native ^b		Hispanic ^c	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Carcinoma	250,124	99.4%	205,618	99.4%	23,187	99.3%	18,041	99.3%	959	99.4%	24,514	99.2%
Epidermoid carcinoma ^d (8051-8131)	158	0.1%	122	0.1%	24	0.1%	-	-	-	-	17	0.1%
Adenocarcinoma ^e	244,659	97.2%	201,440	97.4%	22,335	95.7%	17,705	97.5%	935	96.9%	23,875	96.6%
Adenocarcinoma, NOS (8140)	2,268	0.9%	1,828	0.9%	255	1.1%	144	0.8%	-	-	224	0.9%
Infiltrating duct carcinoma (8500)	177,564	70.6%	144,325	69.8%	17,160	73.5%	13,735	75.6%	709	73.5%	17,748	71.8%
Lobular carcinoma, NOS (8520)	20,768	8.3%	18,270	8.8%	1,395	6.0%	866	4.8%	66	6.8%	1,659	6.7%
Inflammatory adenocarcinoma (8530)	1,485	0.6%	1,168	0.6%	235	1.0%	65	0.4%	-	-	201	0.8%
Infiltrating duct mixed and infiltrating lobular mixed (8522-8524)	27,483	10.9%	23,587	11.4%	1,924	8.2%	1,638	9.0%	98	10.2%	2,623	10.6%
Mucinous adenocarcinoma (8480,8482)	5,911	2.3%	4,735	2.3%	502	2.2%	588	3.2%	20	2.1%	510	2.1%
Mucin-producing adenocarcinoma (8481)	104	0.0%	84	0.0%	-	-	-	-	-	-	-	-
Tubular adenocarcinoma (8211)	2,808	1.1%	2,552	1.2%	123	0.5%	100	0.6%	-	-	185	0.7%
Papillary adenocarcinoma (8050,8260,8503,8504)	1,448	0.6%	1,036	0.5%	225	1.0%	164	0.9%	-	-	178	0.7%
Paget disease (8540-8543)	1,434	0.6%	1,165	0.6%	138	0.6%	113	0.6%	-	-	179	0.7%
Other adenocarcinomas ^f	3,386	1.3%	2,690	1.3%	364	1.6%	287	1.6%	-	-	361	1.5%
Other specific carcinomas ^g	2,459	1.0%	1,822	0.9%	457	2.0%	153	0.8%	-	-	318	1.3%
Medullary adenocarcinoma (8510-8513)	1,148	0.5%	793	0.4%	262	1.1%	78	0.4%	-	-	183	0.7%
Other ^h	1,311	0.5%	1,029	0.5%	195	0.8%	75	0.4%	-	-	135	0.5%
Unspecified, Carcinoma, NOS (8010-8011,8020-8022)	2,848	1.1%	2,234	1.1%	371	1.6%	175	1.0%	-	-	304	1.2%

Source: SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey). Percents may not sum to 100 due to rounding.

^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b Estimates for American Indian/Alaska Native are based on the CHSDA (Contract Health Service Delivery Area) counties.

^c Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

^d Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

^e Epidermoid carcinoma includes squamous, basal, and transitional cell carcinomas.

^f Adenocarcinoma includes histologies 8050, 8140-8147, 8160-8162, 8180-8221, 8250-8507, 8514, 8520-8551, 8560, 8570-8574, 8576, 8940-8941.

^g Other adenocarcinomas include histologies 8141-8147, 8160-8162, 8180-8210, 8212-8221, 8250-8259, 8261-8479, 8483-8499, 8501-8502, 8505-8507, 8514, 8521, 8525-8529, 8531-8539, 8544-8551, 8560, 8570-8574, 8576, 8940-8941.

^h Other specific carcinomas include histologies 8012-8015, 8030-8046, 8150-8155, 8170-8175, 8230-8249, 8508, 8510-8513, 8561-8562, 8575, 8580-8671.

ⁱ Other includes histologies 8012-8015, 8030-8046, 8150-8155, 8170-8175, 8230-8249, 8508, 8561-8562, 8575, 8580-8671.

- Statistic not shown due to fewer than 16 cases during the time period.

Table 4.26 - continued

Cancer of the Female Breast (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2004-2008
Females by Race

Histology ^a	All Races		White		Black		Asian/Pacific Islander		American Indian/ Alaska Native ^b		Hispanic ^c	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Sarcoma and other soft tissue tumors (8680-8713,8800-8921, 9040-9044,9120-9136, 9150-9252,9370-9373, 9540-9582)	306	0.1%	244	0.1%	35	0.1%	22	0.1%	-	-	23	0.1%
Hemangiosarcomas (9120-9126,9170)	160	0.1%	140	0.1%	-	-	-	-	-	-	-	-
Other sarcomas ^d	146	0.1%	104	0.1%	27	0.1%	-	-	-	-	-	-
Other specific types (8720-8790,8930-8936, 8950-9030,9060-9110, 9260-9365,9380-9539)	676	0.3%	520	0.3%	71	0.3%	73	0.4%	-	-	137	0.6%
Phyllodes tumor, malignant (9020)	542	0.2%	418	0.2%	48	0.2%	66	0.4%	-	-	117	0.5%
Other ^e	134	0.1%	102	0.0%	23	0.1%	-	-	-	-	20	0.1%
Unspecified (8000-8005)	483	0.2%	378	0.2%	56	0.2%	25	0.1%	-	-	50	0.2%
Total ^f	251,589	100.0%	206,760	100.0%	23,349	100.0%	18,161	100.0%	965	100.0%	24,724	100.0%

Source: SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey). Percents may not sum to 100 due to rounding.

^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b Estimates for American Indian/Alaska Native are based on the CHSDA (Contract Health Service Delivery Area) counties.

^c Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

^d Other sarcomas include histologies 8680-8713, 8800-8921, 9040-9044, 9127-9136, 9150-9169, 9171-9252, 9370-9373, 9540-9582.

^e Other includes histologies 8720-8790, 8930-8936, 8950-9019, 9021-9030, 9060-9110, 9260-9365, 9380-9539.

^f Total includes carcinoma cases from the previous page.

- Statistic not shown due to fewer than 16 cases during the time period.

Table 4.27

Cancer of the Female Breast(In Situ)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2004-2008
Females by Race

Histology ^a	All Races		White		Black		Asian/Pacific Islander		American Indian/ Alaska Native ^b		Hispanic ^c	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Adenocarcinoma ^d	62,981	99.7%	50,790	99.7%	5,690	99.6%	5,523	99.8%	170	100.0%	5,592	99.8%
Adenocarcinoma <i>in situ</i> , NOS (8140/2)	-	-	-	-	-	-	-	-	-	-	-	-
Ductal carcinoma <i>in situ</i> ^f	52,948	83.8%	42,266	83.0%	4,925	86.2%	5,023	90.8%	138	81.2%	4,771	85.1%
Cribiform carcinoma <i>in situ</i> (8201/2)	5,151	8.2%	4,069	8.0%	456	8.0%	534	9.7%	20	11.8%	481	8.6%
Ductal carcinoma <i>in situ</i> , solid type(8230/2)	3,550	5.6%	2,962	5.8%	255	4.5%	300	5.4%	-	-	297	5.3%
Ductal carcinoma <i>in situ</i> , NOS (8500/2)	21,147	33.5%	17,147	33.7%	1,925	33.7%	1,775	32.1%	58	34.1%	1,817	32.4%
Comedocarcinoma <i>in situ</i> (8501/2)	4,606	7.3%	3,736	7.3%	424	7.4%	388	7.0%	-	-	431	7.7%
Ductal carcinoma <i>in situ</i> papillary(8503/2)	1,079	1.7%	781	1.5%	154	2.7%	114	2.1%	-	-	107	1.9%
Noninfiltrating intracystic carcinoma(8504/2)	301	0.5%	208	0.4%	42	0.7%	44	0.8%	-	-	25	0.4%
Ductal carcinoma <i>in situ</i> micropapillary(8507/2)	1,607	2.5%	1,292	2.5%	179	3.1%	114	2.1%	-	-	145	2.6%
Intraductal with other types of carcinoma <i>in situ</i> (8523/2)	15,305	24.2%	11,904	23.4%	1,478	25.9%	1,734	31.3%	26	15.3%	1,446	25.8%
Lobular carcinoma <i>in situ</i> (8520/2-8521/2, 8524/2)	7,227	11.4%	6,214	12.2%	506	8.9%	301	5.4%	19	11.2%	582	10.4%
Lobular carcinoma <i>in situ</i> , NOS (8520/2)	7,202	11.4%	6,193	12.2%	503	8.8%	300	5.4%	19	11.2%	582	10.4%
Lobular CIS ^f with other CIS ^f (8524/2)	25	0.0%	21	0.0%	-	-	-	-	-	-	-	-
Intraductal and lobular <i>in situ</i> carcinoma (8522/2)	2,370	3.8%	1,976	3.9%	212	3.7%	154	2.8%	-	-	207	3.7%
Other adenocarcinomas ^g	422	0.7%	321	0.6%	47	0.8%	44	0.8%	-	-	32	0.6%
Other <i>in situ</i> histologies ^h	188	0.3%	150	0.3%	25	0.4%	-	-	-	-	-	-
Total	63,169	100.0%	50,940	100.0%	5,715	100.0%	5,532	100.0%	170	100.0%	5,604	100.0%

Source: SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey). Percents may not sum to 100 due to rounding.

^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b Estimates for American Indian/Alaska Native are based on the CHSDA(Contract Health Service Delivery Area) counties.

^c Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

^d Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

^e Adenocarcinoma includes histologies 8050,8140-8147,8160-8162,8180-8221,8230,8250-8507,8514,8520-8551,8560,8570-8574,8576,8940-8941.

^f Ductal carcinoma includes histologies 8201, 8230, 8401, 8500-8507, 8523.

^f CIS = Carcinoma *in situ*.

^g Other adenocarcinomas include 8050, 8141-8147, 8160-8162, 8180-8200, 8202-8221, 8250-8400, 8402-8499, 8514, 8525-8551, 8560, 8570-8574, 8576, 8940-8941.

^h Other histologies include 8000-8049, 8051-8139, 8148-8159, 8163-8179, 8222-8229, 8231-8249, 8508-8513, 8515-8519, 8552-8559, 8561-8569, 8575, 8577-8939, 8942-9989.

- Statistic not shown due to fewer than 16 cases during the time period.

Table 5.16

Cancer of the Cervix Uteri (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2004-2008
Females by Race

Histology ^a	All Races		White		Black		Asian/Pacific Islander		American Indian/ Alaska Native ^b		Hispanic ^c	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Carcinoma	15,406	98.2%	11,706	98.2%	1,972	98.2%	1,403	98.9%	102	97.1%	3,724	98.6%
Epidermoid carcinoma ^d (8050-8131)	10,526	67.1%	7,808	65.5%	1,566	77.9%	925	65.2%	80	76.2%	2,636	69.8%
Squamous cell carcinoma (8070)	6,952	44.3%	5,083	42.6%	1,141	56.8%	593	41.8%	51	48.6%	1,566	41.5%
Squamous cell, keratinizing (8071)	1,137	7.2%	854	7.2%	162	8.1%	100	7.1%	-	-	345	9.1%
Squamous cell, non-keratinizing (8072)	1,451	9.3%	1,119	9.4%	164	8.2%	135	9.5%	-	-	439	11.6%
Squamous cell, Microinvasive (8076)	739	4.7%	571	4.8%	66	3.3%	69	4.9%	-	-	220	5.8%
Other (8050-8069, 8073-8075,8077-8131)	247	1.6%	181	1.5%	33	1.6%	28	2.0%	-	-	66	1.7%
Adenocarcinoma ^e	4,182	26.7%	3,392	28.4%	292	14.5%	421	29.7%	-	-	929	24.6%
Adenocarcinoma, NOS (8140)	2,166	13.8%	1,761	14.8%	138	6.9%	221	15.6%	-	-	485	12.8%
Adenosquamous (8560,8570)	683	4.4%	536	4.5%	67	3.3%	72	5.1%	-	-	174	4.6%
Other adenocarcinomas ^f	1,333	8.5%	1,095	9.2%	87	4.3%	128	9.0%	-	-	270	7.1%
Other specific carcinomas ^g	226	1.4%	177	1.5%	23	1.1%	23	1.6%	-	-	57	1.5%
Unspecified, Carcinoma, NOS (8010-8011,8020-8022)	472	3.0%	329	2.8%	91	4.5%	34	2.4%	-	-	102	2.7%
Sarcoma ^h	79	0.5%	63	0.5%	-	-	-	-	-	-	21	0.6%
Other specific types (8720-8790,8930-8936, 8950-9030,9060-9110, 9260-9365,9380-9539)	129	0.8%	98	0.8%	18	0.9%	-	-	-	-	19	0.5%
Unspecified (8000-8005)	71	0.5%	57	0.5%	-	-	-	-	-	-	-	-
Total	15,685	100.0%	11,924	100.0%	2,009	100.0%	1,418	100.0%	105	100.0%	3,778	100.0%

Source: SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey). Percents may not sum to 100 due to rounding.

^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b Estimates for American Indian/Alaska Native are based on the CHSDA (Contract Health Service Delivery Area) counties.

^c Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

^d Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

^e Epidermoid carcinoma includes squamous, basal, and transitional cell carcinomas.

^f Adenocarcinoma includes histologies 8140-8147,8160-8162,8180-8221,8250-8507,8514,8520-8551,8560,8570-8574,8576,8940-8941.

^g Other adenocarcinomas include histologies 8141-8147,8160-8162,8180-8221,8250-8507,8514,8520-8551,8571-8574,8576,8940-8941.

^h Other specific carcinomas include histologies 8012-8015,8030-8046,8150-8155,8170-8175,8230-8249,8508,8510-8513,8561-8562,8575,8580-8671.

Sarcoma includes histologies 8680-8713,8800-8921,9040-9044,9120-9136,9150-9252,9370-9373,9540-9582.

- Statistic not shown due to fewer than 16 cases during the time period.

Table 6.29

Cancer of the Colon And Rectum (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2004-2008
Both Sexes by Race

Histology ^a	All Races		White		Black		Asian/Pacific Islander		American Indian/ Alaska Native ^b		Hispanic ^c	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Carcinoma	170,815	99.5%	138,167	99.5%	17,517	99.5%	12,709	99.6%	812	98.9%	16,023	99.5%
Epidermoid carcinoma ^d (8051-8131)	777	0.5%	650	0.5%	100	0.6%	-	-	-	-	70	0.4%
Squamous cell carcinoma (8070-8078,8083-8084)	719	0.4%	599	0.4%	95	0.5%	-	-	-	-	59	0.4%
Adenocarcinoma (8050,8140-8147, 8160-8162,8180-8221, 8250-8507,8520-8551,8560, 8570-8574,8576,8940-8941)	161,928	94.3%	131,803	94.9%	16,204	92.0%	11,916	93.4%	751	91.5%	14,997	93.1%
Adenocarcinoma, NOS (8140)	111,564	65.0%	90,474	65.2%	11,223	63.7%	8,636	67.7%	568	69.2%	10,296	63.9%
Adenocarcinoma in adenomatous polyp (8210)	12,357	7.2%	9,984	7.2%	1,081	6.1%	1,019	8.0%	56	6.8%	1,077	6.7%
Adenocarcinoma in villous adenoma (8261)	5,218	3.0%	4,295	3.1%	521	3.0%	335	2.6%	18	2.2%	574	3.6%
Mucinous adenocarcinoma (8470-8473,8480,8482)	12,169	7.1%	10,263	7.4%	1,124	6.4%	676	5.3%	41	5.0%	1,193	7.4%
Mucin-producing adenocarcinoma (8481)	3,223	1.9%	2,606	1.9%	433	2.5%	159	1.2%	-	-	300	1.9%
Signet ring adenocarcinoma (8490)	1,929	1.1%	1,631	1.2%	149	0.8%	134	1.0%	-	-	171	1.1%
Other adenocarcinomas ^e	15,468	9.0%	12,550	9.0%	1,673	9.5%	957	7.5%	52	6.3%	1,386	8.6%
Other specific carcinomas (8012-8015,8030-8046, 8150-8155,8170-8175, 8230-8249,8508,8510-8513, 8561-8562,8575,8580-8671)	6,548	3.8%	4,463	3.2%	1,049	6.0%	673	5.3%	44	5.4%	799	5.0%
Neuroendocrine carcinoid (8240-8245)	5,430	3.2%	3,532	2.5%	944	5.4%	608	4.8%	36	4.4%	702	4.4%
Other ^f	1,118	0.7%	931	0.7%	105	0.6%	65	0.5%	-	-	97	0.6%
Unspecified, Carcinoma, NOS (8010-8011, 8020-8022)	1,562	0.9%	1,251	0.9%	164	0.9%	109	0.9%	-	-	157	1.0%

Source: SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey). Percents may not sum to 100 due to rounding.

^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b Estimates for American Indian/Alaska Native are based on the CHSDA(Contract Health Service Delivery Area) counties.

^c Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

^d Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

^e Epidermoid carcinoma includes squamous, basal, and transitional cell carcinomas.

^f Includes histologies 8050, 8141-8147, 8160-8162, 8180-8204, 8211-8221, 8250-8260, 8262-8264, 8270-8463, 8500-8507, 8514, 8520-8551, 8560, 8570-8574, 8576, 8940-8941.

^f Includes histologies 8012-8015, 8030-8046, 8150-8155, 8170-8175, 8230-8231, 8246-8249, 8508, 8510-8513, 8561-8562, 8575, 8580-8671.

- Statistic not shown due to fewer than 16 cases during the time period.

Table 6.29 - continued

Cancer of the Colon And Rectum (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2004-2008
Both Sexes by Race

Histology ^a	All Races		White		Black		Asian/Pacific Islander		American Indian/ Alaska Native ^b		Hispanic ^c	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Sarcoma and other soft tissue tumors (8680-8713,8800-8921, 8990-8991,9040-9044, 9120-9136,9150-9252, 9370-9373,9540-9582)	99	0.1%	75	0.1%	-	-	-	-	-	-	-	-
Other specific types (8720-8790,8930-8936, 8950-8983,9000-9030, 9060-9110,9260-9365, 9380-9539)	206	0.1%	152	0.1%	26	0.1%	27	0.2%	-	-	23	0.1%
Unspecified (8000-8005)	526	0.3%	442	0.3%	51	0.3%	20	0.2%	-	-	51	0.3%
Total ^d	171,646	100.0%	138,836	100.0%	17,607	100.0%	12,764	100.0%	821	100.0%	16,111	100.0%

Source: SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey). Percents may not sum to 100 due to rounding.

^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b Estimates for American Indian/Alaska Native are based on the CHSDA(Contract Health Service Delivery Area) counties.

^c Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

^d Total includes carcinoma cases from the previous page.

- Statistic not shown due to fewer than 16 cases during the time period.

Table 8.22

Cancer of the Esophagus (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2004-2008
Both Sexes by Race

Histology ^a	All Races		White		Black		Asian/Pacific Islander		American Indian/ Alaska Native ^b		Hispanic ^c	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Carcinoma	16,162	99.2%	13,650	99.2%	1,581	99.3%	762	98.7%	79	100.0%	1,154	99.0%
Epidermoid carcinoma ^d (8051-8131)	5,642	34.6%	3,753	27.3%	1,282	80.5%	543	70.3%	38	48.1%	476	40.8%
Squamous cell carcinoma (8070-8078, 8083-8084)	5,627	34.5%	3,740	27.2%	1,281	80.5%	542	70.2%	38	48.1%	476	40.8%
Adenocarcinoma ^e	9,648	59.2%	9,151	66.5%	234	14.7%	178	23.1%	35	44.3%	623	53.4%
Other specific carcinomas ^f	264	1.6%	225	1.6%	19	1.2%	-	-	-	-	17	1.5%
Unspecified, Carcinoma, NOS (8010-8011,8020-8022)	608	3.7%	521	3.8%	46	2.9%	27	3.5%	-	-	38	3.3%
Other specific types ^g	43	0.3%	31	0.2%	-	-	-	-	-	-	-	-
Unspecified (8000-8005)	94	0.6%	84	0.6%	-	-	-	-	-	-	-	-
Total	16,299	100.0%	13,765	100.0%	1,592	100.0%	772	100.0%	79	100.0%	1,166	100.0%

Source: SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey). Percents may not sum to 100 due to rounding.

^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b Estimates for American Indian/Alaska Native are based on the CHSDA (Contract Health Service Delivery Area) counties.

^c Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

^d Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

^e Epidermoid carcinoma includes squamous, basal, and transitional cell carcinomas.

^f Adenocarcinoma is defined as histologies 8050, 8140-8147, 8160-8162, 8180-8221, 8250-8507, 8514, 8520-8551, 8560, 8570-8574, 8576, 8940-8941.

^g Other specific carcinomas is defined as histologies 8012-8015, 8030-8046, 8150-8155, 8170-8175, 8230-8249, 8508, 8510-8513, 8561-8562, 8575, 8580-8671.

Other specific types includes sarcomas and other soft tissue tumors.

Other specific types is defined as histologies 8680-8713, 8720-8790, 8800-8921, 8930-8936, 8950-9030, 9040-9044, 9060-9110, 9120-9136, 9150-9252, 9260-9365, 9370-9373, 9380-9539, 9540-9582.

- Statistic not shown due to fewer than 16 cases during the time period.

Table 14.22

Cancer of the Liver and Intrahepatic Bile Duct (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2004-2008
Both Sexes by Race

Histology ^a	All Races		White		Black		Asian/Pacific Islander		American Indian/ Alaska Native ^b		Hispanic ^c	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Carcinoma (8010-8576)	18,335	97.3%	12,687	97.0%	2,219	98.4%	3,153	98.0%	158	94.0%	3,047	96.0%
Hepatocellular carcinoma ^d (8170-8175)	14,407	76.5%	9,679	74.0%	1,877	83.2%	2,634	81.9%	125	74.4%	2,481	78.2%
Cholangiocarcinoma (8050,8140-8141, 8160-8161,8260,8440, 8480-8500,8570-8572)	2,913	15.5%	2,282	17.4%	245	10.9%	346	10.8%	24	14.3%	396	12.5%
Intrahepatic cholangio- carcinoma (8160)	2,011	10.7%	1,565	12.0%	156	6.9%	259	8.1%	20	11.9%	275	8.7%
Other cholangiocarcinoma (8050,8140-8141,8161, 8260,8440,8480-8500, 8570-8572)	902	4.8%	717	5.5%	89	3.9%	87	2.7%	-	-	121	3.8%
Other specific carcinomas ^e	398	2.1%	306	2.3%	34	1.5%	52	1.6%	-	-	55	1.7%
Unspecified, Carcinoma, NOS (8010-8011,8020-8022)	356	1.9%	245	1.9%	39	1.7%	61	1.9%	-	-	60	1.9%
Hepatoblastoma (8970)	180	1.0%	145	1.1%	-	-	19	0.6%	-	-	69	2.2%
Sarcoma ^f	165	0.9%	134	1.0%	-	-	16	0.5%	-	-	21	0.7%
Hemangiosarcoma (9120-9133,9161)	99	0.5%	82	0.6%	-	-	-	-	-	-	-	-
Other sarcomas ^g	66	0.4%	52	0.4%	-	-	-	-	-	-	-	-
Other specific types (8720-8790,8930-8936, 8950-8969,8971-9030, 9060-9110,9260-9365,9380-9539)	41	0.2%	25	0.2%	-	-	-	-	-	-	-	-
Unspecified (8000-8005)	120	0.6%	89	0.7%	-	-	18	0.6%	-	-	23	0.7%
Total ^d	18,841	100.0%	13,080	100.0%	2,255	100.0%	3,216	100.0%	168	100.0%	3,173	100.0%

Source: SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey). Percents may not sum to 100 due to rounding.

^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b Estimates for American Indian/Alaska Native are based on the CHSDA (Contract Health Service Delivery Area) counties.

^c Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

^d Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

^e Epidermoid carcinomas arising from liver parenchyma are referred to as hepatocellular carcinomas.

^f Other specific carcinomas include histologies 8012-8015, 8030-8046, 8150-8155, 8177-8180, 8230-8249, 8508, 8510-8513, 8561-8562, 8575, 8580-8671.

^g Sarcoma includes histologies 8680-8713, 8800-8921, 9040-9044, 9120-9136, 9150-9252, 9370-9373, 9540-9582.

^h Other sarcomas include histologies 8680-8713, 8800-8921, 9040-9044, 9135-9136, 9150-9160, 9170-9252, 9370-9373, 9540-9582.

- Statistic not shown due to fewer than 16 cases during the time period.

Table 15.28

Cancer of the Lung and Bronchus (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2004-2008
Both Sexes by Race

Histology ^a	All Races		White		Black		Asian/Pacific Islander		American Indian/ Alaska Native ^b		Hispanic ^c	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Carcinoma	200,102	98.9%	167,178	98.9%	20,217	99.0%	11,263	99.1%	713	98.2%	11,104	98.6%
Small cell (8041-8045)	27,596	13.6%	24,326	14.4%	2,137	10.5%	915	8.0%	136	18.7%	1,300	11.5%
Non-small cell ^d	172,506	85.3%	142,852	84.5%	18,080	88.5%	10,348	91.0%	577	79.5%	9,804	87.1%
Squamous and transitional cell ^e	40,449	20.0%	33,829	20.0%	4,579	22.4%	1,731	15.2%	176	24.2%	1,909	17.0%
Adenocarcinoma ^f	77,926	38.5%	64,188	38.0%	7,550	37.0%	5,713	50.2%	180	24.8%	4,665	41.4%
Large cell (8011-8015)	5,914	2.9%	4,854	2.9%	723	3.5%	298	2.6%	20	2.8%	329	2.9%
Other non-small cell ^g	48,217	23.8%	39,981	23.7%	5,228	25.6%	2,606	22.9%	201	27.7%	2,901	25.8%
Sarcoma ^h	351	0.2%	297	0.2%	31	0.2%	-	-	-	-	33	0.3%
Other specified types ⁱ	159	0.1%	140	0.1%	-	-	-	-	-	-	16	0.1%
Unspecified (8000-8005)	1,691	0.8%	1,431	0.8%	159	0.8%	85	0.7%	-	-	109	1.0%
Total	202,303	100.0%	169,046	100.0%	20,419	100.0%	11,370	100.0%	726	100.0%	11,262	100.0%

Source: SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey). Percents may not sum to 100 due to rounding.

^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b Estimates for American Indian/Alaska Native are based on the CHSDA (Contract Health Service Delivery Area) counties.

^c Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

^d Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

^e Non-small cell includes histologies 8010-8015, 8020-8022, 8030-8040, 8046, 8050-8052, 8070-8084, 8090-8110, 8120-8131, 8140-8156, 8160-8162, 8170-8175, 8180, 8190-8221, 8230-8231, 8240-8263, 8270-8280, 8290-8337, 8340-8347, 8350-8390, 8400-8562, 8570-8576, 8580-8671, 8940-8941.

^f Squamous and transitional cell includes histologies 8051-8052, 8070-8084, 8120-8131.

^g Adenocarcinoma includes histologies 8050, 8140-8149, 8160-8162, 8190-8221, 8250-8263, 8270-8280, 8290-8337, 8350-8390, 8400-8560, 8570-8576, 8940-8941.

^h Other non-small cell includes large cell carcinoma, NOS, other specified carcinomas, and unspecified carcinomas.

ⁱ Other non-small cell is defined as histologies 8010, 8020-8022, 8030-8040, 8046, 8090-8110, 8150-8156, 8170-8175, 8180, 8230-8231, 8240-8249, 8340-8347, 8561-8562, 8580-8671.

^h Sarcoma includes histologies 8680-8713, 8800-8921, 8990-8991, 9040-9044, 9120-9136, 9150-9252, 9370-9373, 9540-9582.

ⁱ Other specific types includes melanomas and is defined as histologies 8720-8790, 8930-8936, 8950-8983, 9000-9030, 9060-9110, 9260-9365, 9380-9539.

- Statistic not shown due to fewer than 16 cases during the time period.

Table 15.29

Cancer of the Lung and Bronchus (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2004-2008
Males by Race

Histology ^a	All Races		White		Black		Asian/Pacific Islander		American Indian/ Alaska Native ^b		Hispanic ^c	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Carcinoma	106,291	98.9%	87,588	98.9%	11,347	99.0%	6,609	99.0%	358	98.1%	6,039	98.7%
Small cell (8041-8045)	13,843	12.9%	12,025	13.6%	1,098	9.6%	619	9.3%	61	16.7%	710	11.6%
Non-small cell ^d	92,448	86.0%	75,563	85.3%	10,249	89.4%	5,990	89.7%	297	81.4%	5,329	87.1%
Squamous and transitional cell ^e	25,417	23.6%	20,972	23.7%	2,928	25.5%	1,312	19.6%	106	29.0%	1,260	20.6%
Adenocarcinoma ^f	37,694	35.1%	30,704	34.7%	3,902	34.0%	2,874	43.0%	75	20.5%	2,265	37.0%
Large cell (8011-8015)	3,378	3.1%	2,743	3.1%	419	3.7%	196	2.9%	-	-	198	3.2%
Other non-small cell ^g	25,959	24.2%	21,144	23.9%	3,000	26.2%	1,608	24.1%	106	29.0%	1,606	26.3%
Sarcoma ^h	204	0.2%	171	0.2%	18	0.2%	-	-	-	-	17	0.3%
Other specified types ⁱ	90	0.1%	80	0.1%	-	-	-	-	-	-	-	-
Unspecified (8000-8005)	896	0.8%	738	0.8%	94	0.8%	53	0.8%	-	-	53	0.9%
Total	107,481	100.0%	88,577	100.0%	11,463	100.0%	6,678	100.0%	365	100.0%	6,116	100.0%

Source: SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey). Percents may not sum to 100 due to rounding.

^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b Estimates for American Indian/Alaska Native are based on the CHSDA (Contract Health Service Delivery Area) counties.

^c Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

^d Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

^e Non-small cell includes histologies 8010-8015, 8020-8022, 8030-8040, 8046, 8050-8052, 8070-8084, 8090-8110, 8120-8131, 8140-8156, 8160-8162, 8170-8175, 8180, 8190-8221, 8230-8231, 8240-8263, 8270-8280, 8290-8337, 8340-8347, 8350-8390, 8400-8562, 8570-8576, 8580-8671, 8940-8941.

^f Squamous and transitional cell includes histologies 8051-8052, 8070-8084, 8120-8131.

^g Adenocarcinoma includes histologies 8050, 8140-8149, 8160-8162, 8190-8221, 8250-8263, 8270-8280, 8290-8337, 8350-8390, 8400-8560, 8570-8576, 8940-8941.

^h Other non-small cell includes large cell carcinoma, NOS, other specified carcinomas, and unspecified carcinomas.

ⁱ Other non-small cell is defined as histologies 8010, 8020-8022, 8030-8040, 8046, 8090-8110, 8150-8156, 8170-8175, 8180, 8230-8231, 8240-8249, 8340-8347, 8561-8562, 8580-8671.

^h Sarcoma includes histologies 8680-8713, 8800-8921, 8990-8991, 9040-9044, 9120-9136, 9150-9252, 9370-9373, 9540-9582.

ⁱ Other specific types includes melanomas and is defined as histologies 8720-8790, 8930-8936, 8950-8983, 9000-9030, 9060-9110, 9260-9365, 9380-9539.

- Statistic not shown due to fewer than 16 cases during the time period.

Table 15.30

Cancer of the Lung and Bronchus (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2004-2008
Females by Race

Histology ^a	All Races		White		Black		Asian/Pacific Islander		American Indian/ Alaska Native ^b		Hispanic ^c	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Carcinoma	93,811	98.9%	79,590	98.9%	8,870	99.0%	4,654	99.2%	355	98.3%	5,065	98.4%
Small cell (8041-8045)	13,753	14.5%	12,301	15.3%	1,039	11.6%	296	6.3%	75	20.8%	590	11.5%
Non-small cell ^d	80,058	84.4%	67,289	83.6%	7,831	87.4%	4,358	92.9%	280	77.6%	4,475	87.0%
Squamous and transitional cell ^e	15,032	15.9%	12,857	16.0%	1,651	18.4%	419	8.9%	70	19.4%	649	12.6%
Adenocarcinoma ^f	40,232	42.4%	33,484	41.6%	3,648	40.7%	2,839	60.5%	105	29.1%	2,400	46.6%
Large cell (8011-8015)	2,536	2.7%	2,111	2.6%	304	3.4%	102	2.2%	-	-	131	2.5%
Other non-small cell ^g	22,258	23.5%	18,837	23.4%	2,228	24.9%	998	21.3%	95	26.3%	1,295	25.2%
Sarcoma ^h	147	0.2%	126	0.2%	-	-	-	-	-	-	16	0.3%
Other specified types ⁱ	69	0.1%	60	0.1%	-	-	-	-	-	-	-	-
Unspecified (8000-8005)	795	0.8%	693	0.9%	65	0.7%	32	0.7%	-	-	56	1.1%
Total	94,822	100.0%	80,469	100.0%	8,956	100.0%	4,692	100.0%	361	100.0%	5,146	100.0%

Source: SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey). Percents may not sum to 100 due to rounding.

^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b Estimates for American Indian/Alaska Native are based on the CHSDA (Contract Health Service Delivery Area) counties.

^c Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

^d Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

^e Non-small cell includes histologies 8010-8015, 8020-8022, 8030-8040, 8046, 8050-8052, 8070-8084, 8090-8110, 8120-8131, 8140-8156, 8160-8162, 8170-8175, 8180, 8190-8221, 8230-8231, 8240-8263, 8270-8280, 8290-8337, 8340-8347, 8350-8390, 8400-8562, 8570-8576, 8580-8671, 8940-8941.

^f Squamous and transitional cell includes histologies 8051-8052, 8070-8084, 8120-8131.

^g Adenocarcinoma includes histologies 8050, 8140-8149, 8160-8162, 8190-8221, 8250-8263, 8270-8280, 8290-8337, 8350-8390, 8400-8560, 8570-8576, 8940-8941.

^h Other non-small cell includes large cell carcinoma, NOS, other specified carcinomas, and unspecified carcinomas.

ⁱ Other non-small cell is defined as histologies 8010, 8020-8022, 8030-8040, 8046, 8090-8110, 8150-8156, 8170-8175, 8180, 8230-8231, 8240-8249, 8340-8347, 8561-8562, 8580-8671.

^h Sarcoma includes histologies 8680-8713, 8800-8921, 8990-8991, 9040-9044, 9120-9136, 9150-9252, 9370-9373, 9540-9582.

ⁱ Other specific types includes melanomas and is defined as histologies 8720-8790, 8930-8936, 8950-8983, 9000-9030, 9060-9110, 9260-9365, 9380-9539.

- Statistic not shown due to fewer than 16 cases during the time period.

Table 20.28

Cancer of the Oral Cavity and Pharynx (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2004-2008
All Races, Both Sexes, by site

Histology ^a	Oral Cavity and Pharynx		Lip		Tongue		Salivary Gland		Floor of Mouth	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Epidermoid carcinoma ^b (8051-8131)	33,054	82.8%	2,522	95.0%	11,107	96.7%	1,008	21.1%	2,132	95.8%
Squamous cell carcinoma (8070-8078,8083-8084)	32,093	80.4%	2,419	91.1%	10,907	94.9%	954	19.9%	2,104	94.5%
Adenocarcinoma ^c	4,432	11.1%	97	3.7%	186	1.6%	3,008	62.9%	73	3.3%
Other specific carcinomas ^d	484	1.2%	-	-	35	0.3%	269	5.6%	-	-
Unspecified, Carcinoma, NOS (8010-8011,8020-8022)	1,438	3.6%	-	-	110	1.0%	320	6.7%	-	-
Sarcoma and soft tissue ^e	172	0.4%	-	-	22	0.2%	50	1.0%	-	-
Other specific types ^f	207	0.5%	-	-	-	-	89	1.9%	-	-
Unspecified (8000-8005)	116	0.3%	-	-	22	0.2%	38	0.8%	-	-
Total	39,903	100.0%	2,656	100.0%	11,491	100.0%	4,782	100.0%	2,226	100.0%

Histology ^a	Gum and Other Mouth		Nasopharynx		Oropharynx and Tonsil		Hypopharynx		Other Oral Cavity and Pharynx	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Epidermoid carcinoma ^b (8051-8131)	4,393	79.9%	1,526	61.9%	7,463	96.9%	2,351	96.2%	552	86.7%
Squamous cell carcinoma (8070-8078,8083-8084)	4,167	75.8%	1,303	52.8%	7,367	95.7%	2,324	95.1%	548	86.0%
Adenocarcinoma ^c	906	16.5%	65	2.6%	55	0.7%	25	1.0%	17	2.7%
Other specific carcinomas ^d	29	0.5%	65	2.6%	38	0.5%	22	0.9%	-	-
Unspecified, Carcinoma, NOS (8010-8011,8020-8022)	50	0.9%	747	30.3%	121	1.6%	30	1.2%	37	5.8%
Sarcoma and soft tissue ^e	31	0.6%	38	1.5%	-	-	-	-	-	-
Other specific types ^f	76	1.4%	16	0.6%	-	-	-	-	-	-
Unspecified (8000-8005)	-	-	-	-	-	-	-	-	-	-
Total	5,500	100.0%	2,466	100.0%	7,702	100.0%	2,443	100.0%	637	100.0%

Source: SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey). Percents may not sum to 100 due to rounding.

^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b Epidermoid carcinoma includes squamous, basal, and transitional cell carcinomas.

^c Adenocarcinoma includes histologies 8050, 8140-8147, 8160-8162, 8180-8221, 8250-8507, 8514, 8520-8551, 8560, 8570-8574, 8576, 8940-8941.

^d Other specific carcinomas includes histologies 8012-8015, 8030-8046, 8150-8155, 8170-8180, 8230-8249, 8508, 8510-8513, 8561-8562, 8575, 8580-8671.

^e Sarcoma and soft tissue includes histologies 8680-8713, 8800-8921, 8990-8991, 9040-9044, 9120-9136, 9150-9252, 9370-9373, 9540-9582.

^f Other specific types includes histologies 8720-8790, 8930-8936, 8950-8983, 9060-9110, 9260-9365, 9380-9539.

- Statistic not shown due to fewer than 16 cases during the time period.

Table 21.16

Cancer of the Ovary (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2004-2008
Females by Race

Histology ^a	All Races		White		Black		Asian/Pacific Islander		American Indian/ Alaska Native ^b		Hispanic ^c	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Carcinoma	22,533	92.1%	19,104	92.5%	1,525	89.1%	1,648	90.9%	106	91.4%	2,556	87.8%
Epidermoid carcinoma ^d (8051-8131)	177	0.7%	134	0.6%	-	-	28	1.5%	-	-	27	0.9%
Adenocarcinoma ^e	20,671	84.5%	17,567	85.1%	1,357	79.3%	1,521	83.9%	96	82.8%	2,280	78.3%
Adenocarcinoma, NOS (8140)	3,223	13.2%	2,701	13.1%	307	17.9%	190	10.5%	-	-	348	12.0%
Papillary adenocarcinoma, NOS (8050,8260)	531	2.2%	455	2.2%	49	2.9%	21	1.2%	-	-	53	1.8%
Clear cell adenocarcinoma (8310,9110)	1,263	5.2%	997	4.8%	40	2.3%	216	11.9%	-	-	126	4.3%
Endometrioid carcinoma (8380-8383,8570)	2,479	10.1%	2,101	10.2%	108	6.3%	234	12.9%	-	-	272	9.3%
Cystadenocarcinoma, NOS (8440,8450)	143	0.6%	113	0.5%	20	1.2%	-	-	-	-	16	0.5%
Serous cystadenocarcinoma (8441)	3,490	14.3%	2,973	14.4%	225	13.1%	243	13.4%	18	15.5%	373	12.8%
Papillary serous cystadenocarcinoma (8460-8462)	6,840	28.0%	5,999	29.1%	430	25.1%	354	19.5%	33	28.4%	720	24.7%
Mucinous cystadenocarcinoma (8470-8473)	519	2.1%	429	2.1%	30	1.8%	48	2.6%	-	-	97	3.3%
Mucinous adenocarcinoma (8480,8482)	880	3.6%	703	3.4%	78	4.6%	87	4.8%	-	-	114	3.9%
Mucin-producing adenocarcinoma(8481)	75	0.3%	62	0.3%	-	-	-	-	-	-	-	-
Other adenocarcinoma ^f	1,228	5.0%	1,034	5.0%	61	3.6%	117	6.5%	-	-	148	5.1%
Other specific carcinomas ^g	544	2.2%	428	2.1%	71	4.1%	36	2.0%	-	-	97	3.3%
Stromal cell tumor (8620-8631,8650)	327	1.3%	240	1.2%	56	3.3%	23	1.3%	-	-	57	2.0%
Other ^h	217	0.9%	188	0.9%	-	-	-	-	-	-	40	1.4%
Unspecified, Carcinoma, NOS (8010,8020-8022)	1,141	4.7%	975	4.7%	86	5.0%	63	3.5%	-	-	152	5.2%

Source: SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey). Percents may not sum to 100 due to rounding.

^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b Estimates for American Indian/Alaska Native are based on the CHSDA(Contract Health Service Delivery Area) counties.

^c Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

^d Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

^e Epidermoid carcinoma includes squamous, basal, and transitional cell carcinomas.

^f Adenocarcinoma includes histologies 8050,8140-8147,8160-8162,8180-8221,8250-8507,8514,8520-8551,8560,8570-8574,8576,8940-8941,9110.

^g Other adenocarcinoma includes histologies 8141-8147,8160-8162,8180-8221,8250-8259,8261-8309,8311-8379,8384-8439,8442-8449,8451-8459,8463-8469,8474-8479,8483-8507,8514,8520-8551,8560,8571-8574,8576,8940-8941.

^h Other specific carcinomas includes histologies 8011-8015,8030-8046,8150-8155,8170-8175,8230-8231,8247-8249,8508,8510-8513,8561-8562,8575,8580-8671.

ⁱ Other subgroup of other specific carcinomas includes histologies 8011-8015,8030-8046,8150-8155,8170-8175,8230-8231,8247-8249,8508,8510-8513,8561-8562,8575,8580-8619,8632-8649,8651-8671.

- Statistic not shown due to fewer than 16 cases during the time period.

Table 21.16 - continued

Cancer of the Ovary (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2004-2008
Females by Race

Histology ^a	All Races		White		Black		Asian/Pacific Islander		American Indian/ Alaska Native ^b		Hispanic ^c	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Sarcoma and other soft tissue tumors (8680-8713,8800-8921, 8990-8991,9040-9044, 9120-9136,9141-9340, 9540-9582)	87	0.4%	67	0.3%	-	-	-	-	-	-	16	0.5%
Other specific types (8240-8246,8720-8790, 8930-8936,8950-8983, 9000-9030,9060-9105, 9350-9364,9380-9513, 9530-9539)	1,629	6.7%	1,307	6.3%	155	9.1%	145	8.0%	-	-	310	10.6%
Mullerian mixed tumor (8950-8951,8980)	697	2.9%	598	2.9%	51	3.0%	43	2.4%	-	-	67	2.3%
Teratoma, malignant (9080-9085,9102)	358	1.5%	267	1.3%	36	2.1%	49	2.7%	-	-	114	3.9%
Other	574	2.3%	442	2.1%	68	4.0%	53	2.9%	-	-	129	4.4%
Unspecified (8000-8005)	206	0.8%	169	0.8%	18	1.1%	-	-	-	-	30	1.0%
Total ^d	24,455	100.0%	20,647	100.0%	1,712	100.0%	1,812	100.0%	116	100.0%	2,912	100.0%

Source: SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey). Percents may not sum to 100 due to rounding.

^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b Estimates for American Indian/Alaska Native are based on the CHSDA(Contract Health Service Delivery Area) counties.

^c Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

^d Total includes carcinoma cases from the previous page.

- Statistic not shown due to fewer than 16 cases during the time period.

Table 22.22

Cancer of the Pancreas (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2004-2008
Both Sexes by Race

Histology ^a	All Races		White		Black		Asian/Pacific Islander		American Indian/ Alaska Native ^b		Hispanic ^c	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Carcinoma	34,274	98.0%	27,914	97.9%	3,718	98.3%	2,319	98.1%	152	96.8%	3,392	97.6%
Epidermoid carcinoma ^d (8051-8131)	63	0.2%	48	0.2%	-	-	-	-	-	-	-	-
Adenocarcinoma ^e	30,041	85.9%	24,509	86.0%	3,249	85.9%	2,009	85.0%	135	86.0%	2,938	84.5%
Adenocarcinoma, NOS (8140)	24,280	69.4%	19,801	69.5%	2,674	70.7%	1,574	66.6%	118	75.2%	2,381	68.5%
Papillary adenocarcinoma, NOS (8260)	60	0.2%	50	0.2%	-	-	-	-	-	-	-	-
Mucinous adenocarcinoma (8480,8482)	995	2.8%	826	2.9%	90	2.4%	72	3.0%	-	-	85	2.4%
Mucin-producing adenocarcinoma (8481)	566	1.6%	453	1.6%	79	2.1%	31	1.3%	-	-	49	1.4%
Infiltrating duct carcinoma (8500-8503,8507,8514)	3,227	9.2%	2,620	9.2%	316	8.4%	266	11.3%	-	-	279	8.0%
Other adenocarcinoma ^f	913	2.6%	759	2.7%	87	2.3%	61	2.6%	-	-	130	3.7%
Other specific carcinomas ^g	2,046	5.8%	1,684	5.9%	204	5.4%	128	5.4%	-	-	215	6.2%
Islet cell carcinoma (8150-8155)	381	1.1%	316	1.1%	32	0.8%	26	1.1%	-	-	31	0.9%
Other carcinomas ^h	1,665	4.8%	1,368	4.8%	172	4.5%	102	4.3%	-	-	184	5.3%
Unspecified, "Carcinoma, NOS" (8010,8020-8022)	2,124	6.1%	1,673	5.9%	258	6.8%	175	7.4%	-	-	235	6.8%
Sarcoma and other soft tissue tumors ⁱ	28	0.1%	25	0.1%	-	-	-	-	-	-	-	-
Other specific types ^j	25	0.1%	18	0.1%	-	-	-	-	-	-	-	-
Unspecified (8000-8005)	655	1.9%	550	1.9%	57	1.5%	41	1.7%	-	-	76	2.2%
Total	34,983	100.0%	28,508	100.0%	3,782	100.0%	2,363	100.0%	157	100.0%	3,476	100.0%

Source: SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey). Percents may not sum to 100 due to rounding.

^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b Estimates for American Indian/Alaska Native are based on the CHSDA (Contract Health Service Delivery Area) counties.

^c Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

^d Epidermoid carcinoma includes squamous, basal, and transitional cell carcinomas.

^e Adenocarcinoma includes histologies 8050,8140-8147,8160-8162,8180-8221,8250-8507,8514,8520-8551,8560,8570-8574,8576,8940-8941.

^f Other adenocarcinoma include histologies 8050,8141-8147,8160-8162,8180-8221,8250-8259,8261-8479,8483-8499,8504-8506,8520-8551,8560,8570-8574,8576,8940-8941.

^g Other specific carcinomas include histologies 8012-8015,8030-8046,8150-8155,8170-8180,8230-8249,8508,8510-8513,8561-8562,8575,8580-8671.

^h Other carcinomas include histologies 8012-8015,8030-8046,8170-8180,8230-8249,8508,8510-8513,8561-8562,8575,8580-8671.

ⁱ Sarcoma and other soft tissue tumors include histologies 8680-8713,8800-8921,8990-8991,9040-9044,9120-9136,9150-9252,9370-9373,9540-9582.

^j Other specific types include histologies 8720-8790,8930-8936,8950-9030,9060-9110,9260-9365,9380-9539.

- Statistic not shown due to fewer than 16 cases during the time period.

Table 24.22

Cancer of the Stomach (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2004-2008
Both Sexes by Race

Histology ^a	All Races		White		Black		Asian/Pacific Islander		American Indian/ Alaska Native ^b		Hispanic ^c	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Carcinoma	26,504	94.5%	19,036	94.9%	3,199	91.3%	3,891	95.5%	202	96.7%	4,653	96.7%
Epidermoid carcinoma ^d (8051-8131)	201	0.7%	145	0.7%	44	1.3%	-	-	-	-	19	0.4%
Squamous cell carcinoma (8070-8078,8083-8084)	192	0.7%	139	0.7%	42	1.2%	-	-	-	-	-	-
Adenocarcinoma (8050,8140-8147, 8160-8162,8180-8221, 8250-8507,8514,8520-8551, 8560,8570-8574, 8576,8940-8941)	24,084	85.9%	17,219	85.8%	2,851	81.4%	3,706	91.0%	180	86.1%	4,225	87.8%
Adenocarcinoma, NOS (8140)	13,787	49.2%	10,180	50.7%	1,630	46.5%	1,805	44.3%	101	48.3%	2,098	43.6%
Adenocarcinoma, intestinal type (8144)	2,334	8.3%	1,380	6.9%	313	8.9%	599	14.7%	27	12.9%	408	8.5%
Carcinoma, diffuse type (8145)	864	3.1%	552	2.8%	85	2.4%	217	5.3%	-	-	184	3.8%
Linitus plastica (8142)	272	1.0%	207	1.0%	24	0.7%	36	0.9%	-	-	67	1.4%
Mucinous adenocarcinoma (8470-8473,8480,8482)	417	1.5%	304	1.5%	64	1.8%	45	1.1%	-	-	60	1.2%
Mucin-producing adenocarcinoma (8481)	219	0.8%	169	0.8%	30	0.9%	19	0.5%	-	-	22	0.5%
Signet ring adenocarcinoma (8490)	5,036	18.0%	3,629	18.1%	572	16.3%	778	19.1%	30	14.4%	1,183	24.6%
Other adenocarcinomas ^e	1,155	4.1%	798	4.0%	133	3.8%	207	5.1%	-	-	203	4.2%
Other specific carcinomas (8012-8015,8030-8046, 8150-8155,8170-8175, 8230-8249,8508,8510-8513, 8561-8562,8575,8580-8671)	1,472	5.2%	1,145	5.7%	194	5.5%	81	2.0%	-	-	277	5.8%
Unspecified, Carcinoma, NOS (8010-8011,8020-8022)	747	2.7%	527	2.6%	110	3.1%	93	2.3%	-	-	132	2.7%

Source: SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey). Percents may not sum to 100 due to rounding.

^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b Estimates for American Indian/Alaska Native are based on the CHSDA (Contract Health Service Delivery Area) counties.

^c Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

^d Epidermoid carcinoma includes squamous, basal, and transitional cell carcinomas.

^e Other adenocarcinomas includes histologies 8050, 8141, 8143, 8146-8147, 8160-8162, 8180-8221, 8250-8469, 8474-8479, 8483-8489, 8491-8507, 8514, 8520-8551, 8560, 8570-8574, 8576, 8940-8941.

- Statistic not shown due to fewer than 16 cases during the time period.

Table 24.22 - continued

Cancer of the Stomach (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2001-2005
Both Sexes by Race

Histology ^a	All Races		White		Black		Asian/Pacific Islander		American Indian/ Alaska Native ^b		Hispanic ^c	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Sarcoma and other soft tissue tumors (8680-8713,8800-8921, 8990-8991,9040-9044, 9120-9136,9150-9252, 9370-9373,9540-9582)	72	0.3%	55	0.3%	-	-	-	-	-	-	-	-
Other specific types (8720-8790,8930-8936, 8950-8983,9000-9030, 9060-9110,9260-9365, 9380-9539)	1,334	4.8%	882	4.4%	279	8.0%	155	3.8%	-	-	136	2.8%
Unspecified (8000-8005)	133	0.5%	94	0.5%	-	-	22	0.5%	-	-	17	0.4%
Total ^d	28,044	100.0%	20,068	100.0%	3,503	100.0%	4,073	100.0%	209	100.0%	4,814	100.0%

Source: SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey). Percents may not sum to 100 due to rounding.

^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b Estimates for American Indian/Alaska Native are based on the CHSDA(Contract Health Service Delivery Area) counties.

^c Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

^d Total includes carcinoma cases from the previous page.

- Statistic not shown due to fewer than 16 cases during the time period.

Table 26.22

Cancer of the Thyroid (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2004-2008
Both Sexes by Race

Histology ^a	All Races		White		Black		Asian/Pacific Islander		American Indian/ Alaska Native ^b		Hispanic ^c	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Carcinoma	42,070	99.7%	34,770	99.8%	2,440	99.5%	4,075	99.8%	167	99.4%	6,087	99.8%
Epidermoid carcinoma ^d (8051-8131)	52	0.1%	45	0.1%	-	-	-	-	-	-	-	-
Adenocarcinoma ^e	40,624	96.3%	33,588	96.4%	2,329	94.9%	3,959	97.0%	160	95.2%	5,894	96.6%
Papillary adenocarcinoma (8050,8260,8340-8344, 8350,8450)	36,370	86.2%	30,141	86.5%	1,947	79.4%	3,612	88.5%	142	84.5%	5,415	88.8%
Follicular carcinoma (8330-8332,8335)	2,648	6.3%	2,087	6.0%	263	10.7%	244	6.0%	-	-	308	5.0%
Oxyphilic (8290)	1,240	2.9%	1,060	3.0%	93	3.8%	72	1.8%	-	-	125	2.0%
Other specific carcinomas ^f	736	1.7%	616	1.8%	61	2.5%	37	0.9%	-	-	106	1.7%
Medullary carcinoma (8510)	698	1.7%	585	1.7%	56	2.3%	36	0.9%	-	-	102	1.7%
Carcinoma, NOS (8004,8010-8012, 8020-8022,8030-8032)	658	1.6%	521	1.5%	49	2.0%	75	1.8%	-	-	79	1.3%
Anaplastic carcinoma (8004,8012,8020-8021, 8030-8032)	406	1.0%	324	0.9%	33	1.3%	44	1.1%	-	-	44	0.7%
Sarcoma and other soft tissue tumors ^g	-	-	-	-	-	-	-	-	-	-	-	-
Other specific types ^h	-	-	-	-	-	-	-	-	-	-	-	-
Unspecified (8000-8003,8005)	102	0.2%	78	0.2%	-	-	-	-	-	-	-	-
Total	42,186	100.0%	34,857	100.0%	2,453	100.0%	4,082	100.0%	168	100.0%	6,100	100.0%

Source: SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey). Percents may not sum to 100 due to rounding.

^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b Estimates for American Indian/Alaska Native are based on the CHSDA (Contract Health Service Delivery Area) counties.

^c Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

^d Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

^e Epidermoid carcinoma includes squamous, basal, and transitional cell carcinomas.

^f Adenocarcinoma includes histologies 8050, 8140-8147, 8160-8162, 8180-8221, 8250-8507, 8514, 8520-8551, 8560, 8570-8574, 8576, 8940-8941.

^g Other specific carcinomas include histologies 8013-8015, 8033-8046, 8150-8155, 8170-8171, 8230-8249, 8510, 8512, 8561-8562, 8575, 8580-8671.

^h Sarcoma and other soft tissue tumors include histologies 8680-8713, 8800-8921, 8990-8991, 9040-9044, 9120-9136, 9150-9252, 9370-9373, 9540-9582.

ⁱ Other specific types include histologies 8720-8790, 8930-8936, 8950-8983, 9000-9030, 9060-9110, 9260-9365, 9380-9539.

- Statistic not shown due to fewer than 16 cases during the time period.